TGFBI corneal dystrophy

Business news, market intelligence, and global industry analysis.

The Latest

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Representative image of a large precious metals mining operation, illustrating the Fresnillo plc share price surge as investors weigh whether the FTSE 100 miner’s 2026 guidance cut is a temporary pause in the silver and gold bull run.

Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?

Representative image of commercial shipping and naval activity in the Strait of Hormuz, as Iran reopens the key oil transit route while uncertainty over the United States naval blockade continues.

Strait of Hormuz reopens on paper, yet ships turn back as Iran and US clash over blockade terms

TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record

FDA clears GenEditBio to begin human testing of GEB-101, a first-in-class genome-editing therapy for TGFBI corneal dystrophy

Find out how GenEditBio's GEB-101 genome-editing therapy just cleared FDA to begin trials for TGFBI corneal dystrophy. Could it redefine in vivo editing?

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

January 7, 2026